AXA : The resistance should give in
Entry price | Target | Stop-loss | Potential |
---|
€0 |
€29.3 |
€24.5 |
+∞% |
---|
Below the resistance zone that is currently being tested, the potential for new gains appears limited for shares in Axa. The stock's technical chart pattern suggests however that the level will be broken.
Summary● In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
Strengths● The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
● The company is one of the best yield companies with high dividend expectations.
● Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The tendency within the weekly time frame is positive above the technical support level at 21.9 EUR
Weaknesses● Technically, the stock approaches a strong medium-term resistance at EUR 25.8.
● According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● The company's earnings releases usually do not meet expectations.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.